Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (Nasdaq: VSTM) announced a proposed underwritten public offering of its common stock, with underwriters granted a 30-day option to buy up to an additional 15% of shares. The offering is subject to market conditions and may not be completed.
Verastem said it will use net proceeds to fund commercial activities for the FDA-approved AVMAPKI FAKZYNJA co-pack for KRAS-mutated recurrent low-grade serous ovarian cancer, continue clinical R&D including the VS-7375 KRAS G12D program, and for working capital. A Form S-3 shelf was declared effective on Nov 20, 2023.
Verastem Oncology (Nasdaq: VSTM) said its management team will present at two investor conferences in November 2025: a Guggenheim Healthcare Conference fireside chat on Tuesday, November 11 at 1:00 pm ET, and a Jefferies Global Healthcare Conference fireside chat in London on Wednesday, November 19 at 2:30 pm GMT (9:30 am ET).
A live webcast of both fireside chats will be available under Events & Presentations on the company investor website and replays will be archived for approximately 90 days after each presentation.
Verastem Oncology (Nasdaq: VSTM) reported Q3 2025 results and business updates on November 4, 2025. Key commercial and clinical highlights include $11.2M net product revenue in the first full quarter post-launch of AVMAPKI FAKZYNJA CO-PACK, completion of planned enrollment for the Phase 3 RAMP 301 trial (270 patients) with an IDMC-recommended one-time +29 patient increase, and VS-7375 clearing 400 mg and 600 mg monotherapy doses with no dose-limiting toxicities.
Financials: total operating expenses $52.0M, GAAP net loss $98.5M (loss per share $1.35), non-GAAP adjusted net loss $39.4M, and cash, cash equivalents and investments of $137.7M, with runway into H2 2026 assuming product revenue and warrant exercises.
Verastem Oncology (Nasdaq: VSTM) reported encouraging preliminary Phase 1/2a data for oral KRAS G12D inhibitor VS-7375. The 400 mg QD and 600 mg QD monotherapy dose levels cleared with no dose-limiting toxicities observed and no nausea, vomiting, or diarrhea > Grade 1 at those doses. Of five efficacy-evaluable patients with at least one scan, 4 of 5 showed tumor reduction and remain on treatment. The study has opened a dose-escalation cohort at 900 mg QD and initiated enrollment of a combination cohort of VS-7375 with cetuximab including colorectal cancer patients. An interim safety and efficacy update is planned for first half of 2026.
Verastem Oncology (Nasdaq: VSTM) will report third quarter 2025 financial results and business updates on Tuesday, November 4, 2025 at 8:00 AM ET. The company will host a conference call and live audio webcast with accompanying slides available in the Investor "Events & Presentations" section at https://investor.verastem.com/events.
Dial-in details: (888) 596-4144 (U.S.) or (646) 968-2525 (international); enter passcode 8194537 at least 10 minutes before the call. A replay of the webcast will be archived and available after the event.
Verastem Oncology (Nasdaq: VSTM) reported updated data from partner GenFleet’s Phase 1/2 monotherapy study of GFH375 (VS-7375 outside China) in advanced KRAS G12D mutant pancreatic ductal adenocarcinoma, presented at ESMO 2025 on October 19, 2025. At the 600 mg daily RP2D, 59 efficacy-evaluable patients showed an ORR of 40.7% (24/59) and a DCR of 96.7% (57/59). Median PFS was 5.52 months (median follow-up 5.65 months); 4-month OS was 92.2% and median OS was not reached. Safety: Grade 3 TRAEs in 30.3%, Grade 4 in 1.5%, dose reductions in 6.1%, discontinuations for TRAEs 3%, and mean relative dose intensity 93%.
Verastem Oncology (Nasdaq: VSTM) granted inducement stock options to nine new employees to purchase 138,000 shares of common stock under Nasdaq Listing Rule 5635(c)(4).
The options carry an exercise price of $8.80 per share (closing price on October 1, 2025). 118,000 options vest 25% after one year, then quarterly over three years, subject to continued service. 20,000 options for one employee vest upon specified business development milestones, subject to continued service.
Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company focused on RAS/MAPK pathway-driven cancer treatments, has announced its participation in two upcoming investor conferences in September 2025.
The company will participate in a fireside chat at the Cantor Global Healthcare Conference on September 3 at 3:55 PM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 at 12:00 PM ET. Both presentations will be available via webcast on the company's investor relations website.
Verastem Oncology (Nasdaq: VSTM) announced promising results from partner GenFleet Therapeutics' Phase 1/2 study of GFH375 (VS-7375) in advanced non-small cell lung cancer (NSCLC) patients with KRAS G12D mutation. The drug demonstrated an impressive 68.8% overall response rate (ORR) at the recommended Phase 2 dose of 600mg QD, and 57.7% ORR across all dose levels.
The study included 142 patients, with 28 having advanced NSCLC. Among NSCLC patients, all had metastatic disease, 64.3% received at least two prior therapies, and 96.4% had prior anti-PD1/PD-L1 therapy. At 600mg QD, the disease control rate reached 93.8%. The safety profile showed manageable adverse events, primarily Grade 1 or 2, with no treatment-related deaths reported.
Verastem Oncology (Nasdaq: VSTM) reported Q2 2025 financial results and significant business updates. The company achieved $2.1 million in net product revenue from AVMAPKI FAKZYNJA CO-PACK in its first six weeks following FDA approval for KRAS-mutated recurrent low-grade serous ovarian cancer. The company ended Q2 with $164.3 million in cash, providing runway into H2 2026.
Key highlights include the first patient dosed in the VS-7375 Phase 1/2a trial for KRAS G12D advanced solid tumors, Fast Track Designation for VS-7375, and positive updated data from the RAMP 205 trial in metastatic pancreatic cancer showing 83% overall response rate. Q2 financial results showed a net loss of $25.9 million, or $0.39 per share, with total operating expenses of $45.9 million.
The company continues to advance multiple clinical programs, including the Phase 3 RAMP 301 trial nearing completion of planned enrollment and expansion of the VS-7375 trial with four new cohorts.